Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

The 25-hydroxyvitamin D levels rose by 14% but this change was not significant (p = 0.12).

Source: 3. Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

All patients were prescribed DPL (DEKAs Plus Liquid, Callion Pharma, Jonesborough, TN, USA) for their vitamin supplementation.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status in 2 to 5 Year-Old Children Using a Cystic Fibrosis-Specific Multivitamin Formulation

Study design awaiting verification · Children · 2026

Original publication title

Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status in 2 to 5 Year-Old Children Using a Cystic Fibrosis-Specific Multivitamin Formulation

Anne Munck; Jeanne Languepin; Raphael Enaud; Frederique Chedevergne; Nathalie Wizla; Natascha Remus; Marie Mittaine; Stephanie Bui; Amelie Arrouy; Megan Quinn; Amy Wahlquist; Isabelle Sermet-Gaudelus

© 2026 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

Abstract: Highlights

What are the main findings?

  • Serum FSV A, D and E levels remained unchanged after 12 months of ETI therapy.

  • ETI therapy improved pancreatic function (FE-1) in young children with CF.

What are the implications of the main findings?

  • The use of provitamin A (β-carotene) supports stable vitamin A levels during ETI therapy.

  • Results support guidance recommendations to prioritize provitamin A in ETI-treated children.

Source: Highlights Source: Highlights

Abstract: Abstract

Background:

Young children with Cystic Fibrosis (CwCF) are at risk of fat-soluble vitamin (FSV) deficiencies due to pancreatic insufficiency, despite pancreatic enzyme supplementation. CFTR modulator therapy such as elexacaftor/tezacaftor/ivacaftor (ETI) may improve pancreatic function, but its impact on FSV levels in this age group remains unclear. We evaluated changes in FSV serum levels in a cohort transitioning to ETI, taking a CF-specific, multivitamin formulation with beta-carotene as the primary source of vitamin A (DEKAs Plus Liquid, DPL).

Methods:

Retrospective data with paired analysis from 23 CwCF (2 to 5 years old) were analyzed. Serum FSV levels (D, E, A) and fecal elastase-1 (FE-1) were measured at baseline and 12 months post-ETI initiation. Daily FSV doses and covariates (FE-1, naive of CFTR modulators and ETI dose) were documented. Statistical analyses included Wilcoxon signed-rank tests and general linear models.

Results:

No significant changes were observed in serum FSV levels, while FSV dosing and formulation remained unchanged. Covariates did not influence serum level changes. Interestingly, ETI significantly improved FE-1 (p = 0.018), with 6/18 children achieving pancreatic sufficiency (FE-1 > 200 µg/g).

Conclusions:

In young CwCF initiating ETI, FSV levels were unchanged while pancreatic function improved. The use of provitamin A (beta-carotene) as in DPL resulted in no change in vitamin A levels and aligns with consensus guidance to prioritize provitamin A in ETI-treated children. Further validation in larger cohorts is warranted.

Source: Abstract
Authors’ abstract

Highlights

What are the main findings?

  • Serum FSV A, D and E levels remained unchanged after 12 months of ETI therapy.

  • ETI therapy improved pancreatic function (FE-1) in young children with CF.

What are the implications of the main findings?

  • The use of provitamin A (β-carotene) supports stable vitamin A levels during ETI therapy.

  • Results support guidance recommendations to prioritize provitamin A in ETI-treated children.

Abstract

Background:

Young children with Cystic Fibrosis (CwCF) are at risk of fat-soluble vitamin (FSV) deficiencies due to pancreatic insufficiency, despite pancreatic enzyme supplementation. CFTR modulator therapy such as elexacaftor/tezacaftor/ivacaftor (ETI) may improve pancreatic function, but its impact on FSV levels in this age group remains unclear. We evaluated changes in FSV serum levels in a cohort transitioning to ETI, taking a CF-specific, multivitamin formulation with beta-carotene as the primary source of vitamin A (DEKAs Plus Liquid, DPL).

Methods:

Retrospective data with paired analysis from 23 CwCF (2 to 5 years old) were analyzed. Serum FSV levels (D, E, A) and fecal elastase-1 (FE-1) were measured at baseline and 12 months post-ETI initiation. Daily FSV doses and covariates (FE-1, naive of CFTR modulators and ETI dose) were documented. Statistical analyses included Wilcoxon signed-rank tests and general linear models.

Results:

No significant changes were observed in serum FSV levels, while FSV dosing and formulation remained unchanged. Covariates did not influence serum level changes. Interestingly, ETI significantly improved FE-1 (p = 0.018), with 6/18 children achieving pancreatic sufficiency (FE-1 > 200 µg/g).

Conclusions:

In young CwCF initiating ETI, FSV levels were unchanged while pancreatic function improved. The use of provitamin A (beta-carotene) as in DPL resulted in no change in vitamin A levels and aligns with consensus guidance to prioritize provitamin A in ETI-treated children. Further validation in larger cohorts is warranted.

Publication and source details

Original title: Impact of Elexacaftor/Tezacaftor/Ivacaftor on Fat-Soluble Vitamin Status in 2 to 5 Year-Old Children Using a Cystic Fibrosis-Specific Multivitamin Formulation

Anne Munck; Jeanne Languepin; Raphael Enaud; Frederique Chedevergne; Nathalie Wizla; Natascha Remus; Marie Mittaine; Stephanie Bui; Amelie Arrouy; Megan Quinn; Amy Wahlquist; Isabelle Sermet-Gaudelus

Children · 2026

* Correspondence: anne.munck1@gmail.com© 2026 by the authors.2026https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Alveolus Biomedical BVThe Article Processing Charge was funded by Alveolus Biomedical BV, Entrepotdok 177, 1018AD Amsterdam, The Netherlands.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:13:29.731986+00:00

DOI: 10.3390/children13070868 · PMC13407151